Please login to the form below

Not currently logged in
Email:
Password:

Pfizer phase III Lyrica success

Pfizer has recorded positive results in a phase III trial of fibromyalgia treatment Lyrica

Pfizer has recorded positive results in a phase III trial of Lyrica (pregabalin), a potential new treatment for fibromyalgia -  a disabling disorder that adversely affects quality of life.

The study demonstrated a statistically significant reduction in the endpoint mean pain score recorded by participants, with the drug demonstrating efficacy and safety.

The drug was compared to placebo, with 501 subjects involved across 45 investigative sites in Japan.

"We are pleased with the top-line results of this study and look forward to more fully understanding the potential benefits that Lyrica may bring to fibromyalgia patients in Japan," said Dr Akihisa Harada, vice president, head of development, at Pfizer Japan.

The most common adverse events in the study were somnolence, dizziness, weight increased, constipation, feeling abnormal, edema peripheral and blurred vision.

7th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics